2020
Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery 2020, 155: e195047. PMID: 31800002, PMCID: PMC6902102, DOI: 10.1001/jamasurg.2019.5047.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaNational Cancer DatabaseWhite patientsBlack patientsAdvanced diseaseOverall survivalClinical parametersDisease stageCancer DatabaseSurgical proceduresMultivariable Cox proportional hazards regression modelingTreatment inequitiesCox proportional hazards regression modelingPancreatic ductal adenocarcinoma (PDAC) survivalUnadjusted median overall survivalYounger ageProportional hazards regression modelingMedian overall survivalModest survival advantageStage II diseaseNew cancer diagnosesLess chemotherapyResectable cancerCohort studyPrimary outcome
2017
Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker‐Prietz A, Chen L, Laheru DA, De Jesus‐Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang C, Zheng L. Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine 2017, 6: 1552-1562. PMID: 28639410, PMCID: PMC5504321, DOI: 10.1002/cam4.1104.Peer-Reviewed Original ResearchConceptsMedian overall survivalUpfront chemotherapyNeoadjuvant chemotherapyNeoadjuvant therapySurgical resectionOverall survivalUpfront chemoradiationBorderline resectable pancreatic adenocarcinomaLong-term survival benefitBorderline resectable pancreatic cancerCurative surgical resectionResectable pancreatic cancerUpfront neoadjuvant chemotherapyResectable pancreatic adenocarcinomaSubpopulation of patientsJohns Hopkins HospitalLong-term survivalCurative intentNeoadjuvant chemoradiationConsecutive patientsSurvival benefitPancreatic cancerPancreatic adenocarcinomaRetrospective analysisChemoradiationA Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients
van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M. A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients. Clinical Cancer Research 2017, 23: 2006-2018. PMID: 27756787, DOI: 10.1158/1078-0432.ccr-16-1236.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAutoantigensBiomarkers, TumorCarcinoma, Renal CellDisease-Free SurvivalDNA MethylationFemaleHigh-Throughput Nucleotide SequencingHumansIntercellular Signaling Peptides and ProteinsKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedNeurofilament ProteinsNon-Fibrillar CollagensOligonucleotide Array Sequence AnalysisPrognosisPromoter Regions, GeneticProportional Hazards ModelsUbiquitin-Protein LigasesConceptsClear cell renal cell carcinomaPrognostic modelNonmetastatic clear cell renal cell carcinomaMethylation markersCox proportional hazards modelPrimary clear cell renal cell carcinomaIndependent patient seriesCause-specific survivalOutcomes of patientsCell renal cell carcinomaPrognosis of patientsKaplan-Meier curvesLog-rank testConfidence intervalsCurrent prognostic modelsRenal cell carcinomaProportional hazards modelClin Cancer ResCcRCC cell linesCancer Genome AtlasClinicopathologic featuresPatient seriesCell carcinomaMethylation-specific PCRPoor survival
2016
IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers
Fu T, Pappou EP, Guzzetta AA, de Freitas Calmon M, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N. IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. Annals Of Surgery 2016, 263: 337-344. PMID: 25822686, PMCID: PMC4648704, DOI: 10.1097/sla.0000000000001204.Peer-Reviewed Original ResearchConceptsStage II colorectal cancerRisk of recurrenceIGFBP-3 methylationLymph nodesColorectal cancerHazard ratioPrimary tumorHigh riskIndependent cohortFive-year recurrence-free survival ratesRecurrence-free survival ratesHigh-risk patientsSignificant prognostic factorsIdentification of patientsProportional hazards modelIGFBP-3Prognostic factorsTumor characteristicsPredicts RecurrenceHazards modelPatientsRecurrenceSurvival rateMultivariate analysisSurgery
2015
Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma
Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, Cameron JL, Herman JM, Ahuja N, Lennon AM, Weiss MJ, Wood LD, Wolfgang CL. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. Hepato Pancreato Biliary 2015, 18: 236-246. PMID: 27017163, PMCID: PMC4814593, DOI: 10.1016/j.hpb.2015.10.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Pancreatic DuctalDatabases, FactualDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Second PrimaryPancreatectomyPancreatic NeoplasmsProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPancreatic ductal adenocarcinomaNon-invasive intraductal papillary mucinous neoplasmsIntermediate-grade dysplasiaPapillary mucinous neoplasmRemnant pancreasVascular invasionMucinous neoplasmsDuctal adenocarcinomaInvasive pancreatic ductal adenocarcinomaMedian overall survivalLymph node metastasisRate of progressionSubsequent developmentIntermediate dysplasiaPancreatic resectionOverall survivalNode metastasisPerineural invasionMalignant entitiesRisk factorsPatientsDysplasiaPancreas
2014
Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, Glöckner SC, Tessema M, Van Neste L, Easwaran H, Schuebel KE, Licchesi J, Hooker CM, Ahuja N, Amano J, Belinsky SA, Baylin SB, Herman JG, Brock MV. Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer. Clinical Cancer Research 2014, 20: 1856-1864. PMID: 24486589, PMCID: PMC4019442, DOI: 10.1158/1078-0432.ccr-13-2109.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerThree-gene panelLung cancerIndependent cohortPrimary NSCLC samplesCell lung cancerNSCLC cell linesNovel diagnostic biomarkersAdjuvant chemotherapyMolecular diagnostic testsCancer Genome AtlasCancer mortalityCancer-specific methylationSurgical specimensNSCLC samplesMolecular stagingEarly diagnosisDiagnostic biomarkersNormal tissuesDiagnostic testsCohortCancerGenome AtlasMethylation biomarkersCell lines
2013
Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer
Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A, Wolfgang C, Pappou EP, Iacobuzio-Donahue CA, Goggins MG, Herman JG, Wang TH, Baylin SB, Ahuja N. Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer. Clinical Cancer Research 2013, 19: 6544-6555. PMID: 24088737, PMCID: PMC4310572, DOI: 10.1158/1078-0432.ccr-12-3224.Peer-Reviewed Original ResearchADAM ProteinsADAMTS1 ProteinBiomarkers, TumorCarcinoma in SituCell Line, TumorCell MovementCell ProliferationCpG IslandsDNADNA MethylationDNA-Binding ProteinsEarly Detection of CancerEpigenesis, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMolecular Diagnostic TechniquesPancreatic NeoplasmsPromoter Regions, GeneticProportional Hazards ModelsSensitivity and SpecificitySequence Analysis, DNATranscription FactorsTranscriptome2564 resected periampullary adenocarcinomas at a single institution: trends over three decades
He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. Hepato Pancreato Biliary 2013, 16: 83-90. PMID: 23472829, PMCID: PMC3892319, DOI: 10.1111/hpb.12078.Peer-Reviewed Original ResearchConceptsPeriampullary adenocarcinomaBile ductSingle institutionPancreatic cancerIntraductal papillary mucinous neoplasmNumber of patientsPapillary mucinous neoplasmRelative survival ratesCurative intentWorse survivalLongterm outcomesMucinous neoplasmsSafe resectionLongterm survivalPathological diagnosisPrimary siteSurvival ratePancreaticoduodenectomyAdenocarcinomaPatientsSurvivalResectionSignificant differencesCancerDiagnosis
2012
CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis
Fu T, Pappou EP, Guzzetta AA, Jeschke J, Kwak R, Dave P, Hooker CM, Morgan R, Baylin SB, Iacobuzio-Donahue CA, Wolfgang CL, Ahuja N. CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis. Clinical Cancer Research 2012, 18: 4743-4752. PMID: 22825585, PMCID: PMC3482463, DOI: 10.1158/1078-0432.ccr-12-0707.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinomaAgedCpG IslandsDNA MethylationDuodenal NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMicrosatellite InstabilityMiddle AgedMutL Protein Homolog 1Nuclear ProteinsPrognosisProportional Hazards ModelsProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Ras ProteinsConceptsMLH1 methylation statusDuodenal adenocarcinomaMicrosatellite instabilityPoor prognosisBRAF mutationsMLH1 methylationCox proportional hazards modelDuodenal adenocarcinoma patientsKaplan-Meier analysisSignificant prognostic valueCpG island methylator phenotype (CIMP) statusProportional hazards modelBRAF V600E mutationMethylation statusWorse OSOverall survivalClinicopathologic featuresTumor characteristicsAdenocarcinoma patientsPrognostic valueKRAS mutationsMSI statusHazards modelAdenocarcinomaV600E mutation
2011
Early-Stage Gallbladder Cancer in the Surveillance, Epidemiology, and End Results Database: Effect of Extended Surgical Resection
Downing SR, Cadogan KA, Ortega G, Oyetunji TA, Siram SM, Chang DC, Ahuja N, Leffall LD, Frederick WA. Early-Stage Gallbladder Cancer in the Surveillance, Epidemiology, and End Results Database: Effect of Extended Surgical Resection. JAMA Surgery 2011, 146: 734-738. PMID: 21690451, DOI: 10.1001/archsurg.2011.128.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCholecystectomyFemaleGallbladder NeoplasmsHumansLymph Node ExcisionMaleMiddle AgedProportional Hazards ModelsSEER ProgramSurvival RateConceptsEarly-stage gallbladder cancerEnd Results (SEER) databaseMore lymph nodesLymph nodesGallbladder cancerSurgical resectionSurvival benefitT2 lesionsResults databaseMultivariate analysisDisease-positive lymph nodesPrimary gallbladder cancerExtended surgical resectionLN excisionOverall survivalSimple cholecystectomyAdvanced cancerFemale patientsCertain patientsRetrospective analysisSurgical proceduresSurvival advantagePatientsCancerResectionGenomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer
Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glöckner SC, de Freitas Calmon M, Hooker CM, Funes JM, Boshoff C, Smits KM, van Engeland M, Weijenberg MP, Iacobuzio-Donahue CA, Herman JG, Schuebel KE, Baylin SB, Ahuja N. Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer. Clinical Cancer Research 2011, 17: 1535-1545. PMID: 21278247, PMCID: PMC3077819, DOI: 10.1158/1078-0432.ccr-10-2509.Peer-Reviewed Original ResearchConceptsDNA methylationExtracellular matrixDNA methylation analysisEpigenetic mechanismsKey genesEpigenomic alterationsCore pathwaysEpigenetic abnormalitiesPathway genesECM genesMultiple genesEpigenetic alterationsPathway componentsPathway analysisIntegrative analysisLarge CRC cohortsGenesMethylationMethylation analysisSimultaneous methylationPathway disruptionPathwayAggregate roleNovel prognostic biomarkerEVL
2010
Disparity in limb-salvage surgery among sarcoma patients
Downing S, Ahuja N, Oyetunji TA, Chang D, Frederick WA. Disparity in limb-salvage surgery among sarcoma patients. The American Journal Of Surgery 2010, 199: 549-553. PMID: 20359572, DOI: 10.1016/j.amjsurg.2009.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmputation, SurgicalAsianBlack or African AmericanFemaleHealth Services AccessibilityHealthcare DisparitiesHispanic or LatinoHumansLimb SalvageLogistic ModelsMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantSarcomaSEER ProgramUnited StatesWhite PeopleConceptsLimb-sparing proceduresLimb salvage surgeryLimb salvagePreoperative radiationSarcoma patientsAfrican AmericansEnd Results (SEER) databaseAfrican American patientsSpecific surgical proceduresWhite patientsResults databaseTreatment modalitiesAmerican patientsSurgical proceduresPatientsMultivariate analysisBivariate analysisLogistic regressionSalvageSurgerySurvivalRecent studiesPrevious studiesTumorsAmericans
2009
Predictors of Survival After Resection of Retroperitoneal Sarcoma
Nathan H, Raut CP, Thornton K, Herman JM, Ahuja N, Schulick RD, Choti MA, Pawlik TM. Predictors of Survival After Resection of Retroperitoneal Sarcoma. Annals Of Surgery 2009, 250: 970-976. PMID: 19644351, PMCID: PMC3099434, DOI: 10.1097/sla.0b013e3181b25183.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantInfant, NewbornKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPostoperative PeriodPrognosisProportional Hazards ModelsRetroperitoneal NeoplasmsRetrospective StudiesRisk FactorsSarcomaSEER ProgramSurvival RateTime FactorsUnited StatesYoung AdultConceptsPrimary retroperitoneal sarcomaRetroperitoneal sarcomaPredictors of survivalAJCC staging systemTumor sizeStaging systemRPS resectionHistological subtypesCurrent AJCC staging systemPatients Undergoing ResectionDiscriminatory abilityEnd Results (SEER) databaseAmerican Joint CommitteeCancer (AJCC) staging systemLymph node metastasisModerate discriminatory abilityMalignant fibrous histiocytomaProportional hazards modelPoor discriminatory abilityPrevalent histologyUndergoing resectionNode metastasisAJCC stageMultivariable analysisResults database